ACLS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miltiadous, G.
Right arrow Articles by Elisaf, M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miltiadous, G.
Right arrow Articles by Elisaf, M. S.
Annals of Clinical & Laboratory Science 36:353-355 (2006)
© 2006 Association of Clinical Scientists

Brief Communication

Plasma Lipoprotein(a) Levels and LDL-Cholesterol Lowering Response to Statin Therapy in Patients with Heterozygous Familial Hypercholesterolemia

George Miltiadous1, Vasilios Saougos1, Marios Cariolou2 and Moses S. Elisaf1
1 Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece, and 2 Molecular Genetics Department, Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus

Address correspondence to Moses S. Elisaf, M.D., Department of Internal Medicine, University of Ioannina, Ioannina 451 10, Greece; tel 302 651 097509; fax 302 651 097016; e-mail: me00521{at}cc.uoi.gr.

Familial hypercholesterolemia (FH) is characterised by elevated plasma LDL-cholesterol levels and premature ischemic heart disease. Statin therapy is mandatory in order to prevent atherosclerosis in patients with heterozygous FH. Both genetic and environmental factors affect the statin-induced LDL-cholesterol lowering effect in patients with heterozygous FH. Recently published data suggest that plasma lipoprotein(a) levels may affect the efficacy of statin therapy in patients with nephrotic syndrome. However, no data are available concerning the effect of lipoprotein(a) levels on the efficacy of statin therapy in patients with heterozygous FH. This report demonstrates negative correlation between plasma lipoprotein(a) levels and the LDL-cholesterol lowering effect of statin therapy in 49 patients with heterozygous FH.

Keywords: Lipoprotein(a), familial hypercholesterolemia, statins






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the Association of Clinical Scientists.